Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00037765 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Gene Modifiers of Cystic Fibrosis Lung Disease

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Jul 2026 to Jul 2027v26
  2. Primary and study completion dates: Jul 2024 to Jul 2026v25
  3. Primary and study completion dates: Jul 2023 to Jul 2024 Eligibility criteria expanded, about 14 words · Publications: 48 to 51v24 Show 2 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Publications: 48 to 51

    See this version in full on ClinicalTrials.gov ↗

  4. Primary and study completion dates: Jul 2022 to Jul 2023 Publications: 32 to 48v23 Show 1 more changeShow less
    • Publications: 32 to 48

    See this version in full on ClinicalTrials.gov ↗

  5. Primary and study completion dates: Jul 2021 to Jul 2022v22
Show 20 earlier versionsHide 20 earlier versions
  1. Study site revisedv21 See this version in full on ClinicalTrials.gov ↗
  2. Primary and study completion dates: Jul 2019 to Jul 2021v20
  3. Primary and study completion dates: Jul 2018 to Jul 2019 Publications: 20 to 32v19 Show 1 more changeShow less
    • Publications: 20 to 32

    See this version in full on ClinicalTrials.gov ↗

  4. Collaborators expanded, about 7 wordsv18 See this version in full on ClinicalTrials.gov ↗
  5. Primary and study completion dates: Jul 2017 to Jul 2018v17
  6. Primary and study completion dates: Jul 2016 to Jul 2017v16
  7. Re-verified, no change to tracked fieldsv15
  8. Primary and study completion dates: Jul 2015 to Jul 2016v14
  9. Re-verified, no change to tracked fieldsv13
  10. Trial status: Recruiting to Active, Not Recruiting Site details revisedv12 Show 1 more changeShow less
    • Site details revised
  11. Publications: 6 to 20v11 See this version in full on ClinicalTrials.gov ↗
  12. Primary and study completion dates: Aug 2012 to Jul 2015v10
  13. Collaborators shortened, about 7 wordsv9 See this version in full on ClinicalTrials.gov ↗
  14. Primary and study completion dates: Aug 2011 to Aug 2012 Publications: 5 to 6v8 Show 1 more changeShow less
    • Publications: 5 to 6

    See this version in full on ClinicalTrials.gov ↗

  15. Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI) to University of North Carolina, Chapel Hill Collaborators expanded, about 7 words · Publications: 1 to 5v7 Show 2 more changesShow less
    • Collaborators expanded, about 7 words
    • Publications: 1 to 5

    See this version in full on ClinicalTrials.gov ↗

  16. Re-verified, no change to tracked fieldsv6
  17. Study title revisedv5 See this version in full on ClinicalTrials.gov ↗
  18. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v4 Show 1 more changeShow less
    • Study sites: 0 to 1
  19. Trial status: Active, Not Recruiting to Not Yet Recruiting Enrollment target: 600 · Primary completion date: Aug 2011 · Completion date: Aug 2006 to Aug 2011 · 1 morev3 Show 4 more changesShow less
    • Enrollment target: 600
    • Primary completion date: Aug 2011
    • Completion date: Aug 2006 to Aug 2011
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  20. Study Status, Referencesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to examine genetic modifiers of the severity of cystic fibrosis lung disease.
Trial Details
NCT Number NCT00037765
Lead Sponsor University of North Carolina, Chapel Hill
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Cystic Fibrosis, Lung Diseases
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov